Category: immunotherapy

The landscape of cancer treatment has been revolutionized in recent years with the advent of immunotherapy, a cutting-edge approach that harnesses the power of the body’s immune system to combat cancer cells. In non-small cell lung cancer (NSCLC), immunotherapy has emerged as a promising treatment option, particularly in patients with specific genetic mutations such as […]

The biotech industry is currently experiencing a remarkable convergence of clinical breakthroughs in the field of immunotherapy. This cutting-edge sector, which focuses on leveraging the body’s immune system to fight diseases like cancer, has seen unprecedented growth, with the global immunotherapy market surpassing a staggering $136 billion. This surge in market value is indicative of […]

In the realm of food allergy management, the landscape is continuously shifting, presenting both challenges and opportunities for clinicians seeking to provide optimal care. One beacon of guidance in this ever-evolving field is the Food Allergy Support Team (FAST), a nonprofit organization dedicated to equipping clinicians with resources and education to navigate the complexities of […]

Research recently presented at the ASPC 2025 Congress on CVD Prevention sheds light on the heightened cardiovascular risks faced by patients with both rheumatoid arthritis (RA) and metabolic dysfunction-associated steatohepatitis (MASH). Dr. Rayan Salih from Northeast Georgia Health System highlighted how the coexistence of these conditions significantly increases the rates of non-ST-segment elevation myocardial infarction […]

In a quest to enhance the immunotherapy options available for patients with acute myeloid leukemia (AML), researchers have delved into the surface proteome of a diverse array of AML samples. This exploration has unveiled promising antigens and primitive cell markers that offer insights into the heterogeneity of AML subgroups. The study published inCell Reportsintroduces a […]

ZEPOSIA® (ozanimod), a Sphingosine 1-Phosphate Receptor Modulator for Relapsing Forms of Multiple Sclerosis In collaboration with Bristol Myers Squibb, this Clinical Brief delves into the realm of sphingosine 1-phosphate receptor modulators for relapsing forms of multiple sclerosis (MS), shedding light on the outcomes from the phase 3 SUNBEAM and RADIANCE trials for ZEPOSIA®(ozanimod). Dr. Jeffrey […]

In the realm of healthcare, the integration of structured care pathways and predictive modeling stands as a pivotal solution to combat primary care workforce shortages and the escalating demands of managing chronic diseases comprehensively. Leveraging artificial intelligence (AI) and predictive modeling can revolutionize clinical decision-making by pinpointing high-risk patients, offering real-time guidance, and suggesting evidence-based […]

Phosphatidylinositol 3-kinase (PI3K) inhibitors have emerged as promising therapeutic targets for cancer treatment, with idelalisib and copanlisib leading the way in treating various malignancies such as chronic lymphocytic leukemia and follicular lymphoma. These agents have shown significant efficacy in clinical trials, with idelalisib boasting an overall response rate of 54% in follicular lymphoma and 61% […]

In a groundbreaking randomized trial, low-dose aspirin has demonstrated a remarkable ability to slash recurrence rates in patients with PI3K pathway gene alterations, offering a beacon of hope in the landscape of colorectal cancer treatment. Over a 3-year period, recurrence rates were nearly cut in half compared to a placebo, emphasizing the potential of aspirin […]

In the realm of hematologic malignancies, a recent analysis has shed light on a critical correlation between higher tumor mutational burden (TMB) and PD-L1 expression, and the grim reality of shorter survival. This revelation, mirroring findings in solid tumors, underscores the significance of these biomarkers in predicting patient outcomes. Published in Therapeutic Advances in Medical […]

Iron dysregulation has emerged as a pivotal player in the progression of multiple sclerosis (MS), intertwining with neuroinflammation, demyelination, and offering potential avenues for therapeutic interventions. The intricate relationship between iron levels and the pathophysiology of MS unravels a captivating saga of how this essential mineral can shape the course of a debilitating autoimmune condition, […]

Lymph nodes, often overlooked in the grand scheme of cancer treatment, have been revealed to be pivotal command centers orchestrating immune attacks. Recent research has unveiled that surgically excising these nodes alongside tumors could inadvertently diminish treatment efficacy, while preserving them has the potential to amplify therapeutic outcomes significantly. For nearly a century, the standard […]

For years, the diabetes community has sought innovative solutions to reduce the burden of insulin injections, particularly for individuals managing type 1 diabetes. At the forefront of this quest, a groundbreaking lipid-based carrier technology was unveiled at the 252nd meeting of the American Chemical Society in Philadelphia. This cutting-edge development aims to revolutionize insulin delivery […]

In the realm of oncology, the COCOON study emerges as a beacon of hope, shedding light on a novel dermatology management approach that markedly diminishes skin-related adverse effects in patients battling lung cancer and undergoing treatment with amivantamab and lazertinib. Dr. Byoung Chul Cho, a distinguished medical oncologist at the Yonsei Cancer Center in the […]

In the realm of cancer treatment, hope shines bright for patients battling heavily pretreated microsatellite stable metastatic colorectal cancer (CRC). The key to this newfound optimism lies in treatment combinations based on immune checkpoint inhibitors (ICI), offering a beacon of survival benefits in the fight against this aggressive disease. Empowering Patients with Innovative Treatment Combinations […]

A pharmacist-led clinic has revolutionized the management of venetoclax ramp-up for chronic lymphocytic leukemia (CLL) patients at low to moderate risk of tumor lysis syndrome (TLS), as revealed in a recent study. The clinic achieved an impressive 94.3% success rate in reaching the target 400 mg dose, with minimal instances of serious TLS, enhancing patient […]

In the realm of clinical development, where the symphony of science and strategy converge, the dance of bispecific therapies takes center stage. A harmonious blend of innovation and regulation, these dual-targeting antibodies hold the promise of revolutionizing treatment paradigms for hematologic malignancies and beyond. As we delve into the intricate web of managed care considerations […]

In the realm of multiple myeloma treatment, a new horizon beckons, illuminated by the promising glow of BCMA-targeted bispecific antibodies. Dr. Shaji Kumar, a luminary at the Mayo Clinic, guides us through the labyrinthine paths of linvoseltamab, teclistamab, and elranatamab, shedding light on their selection criteria, outcomes, and the palpable impact they wield in the […]

Bispecific antibodies are the new gladiators in the arena of cancer treatment, and the recent unveiling of MagnetisMM-20 at the 66th American Society of Hematology Annual Meeting & Exposition has set the stage on fire. This groundbreaking study showcased the potential of combining elranatamab with carfilzomib, a proteasome inhibitor, to elicit responses even in patients […]

In the realm of immunotherapy, the emergence of SB17, a groundbreaking ustekinumab biosimilar, has orchestrated a harmonious blend of efficacy and safety for patients grappling with psoriasis and psoriatic arthritis, resonating with the melody of enhanced patient experience and convenience. An enlightening review article has meticulously delineated the symphony of evidence that fortifies the foundation […]

In the realm of value-based oncology care, the erudite Jason Bergsbaken, PharmD, MBA, BCOP, shines a light on the labyrinthine operational challenges. He deftly underscores the delicate equilibrium required to harmonize standardized treatment pathways with the malleability essential for personalized, biomarker-driven care. At a recent gathering under the aegis of the Institute for Value-Based Medicine®, […]

The biosimilar market landscape is undergoing a significant transformation, with notable trends and challenges highlighted in the latest report by Samsung Bioepis. The market shares of adalimumab biosimilars have been steadily increasing, driven by factors such as pricing strategies and government support. From May to August 2024, there was a 4% rise in adalimumab biosimilar […]

Reducing the reliance on oral corticosteroids in patients with severe asthma is a critical mission, given the adverse effects, healthcare costs, and impact on quality of life associated with these medications. A study published in Allergy emphasized the urgent necessity for clear tapering guidelines and collaborative patient-provider strategies to address the significant adverse effects and […]

In the dynamic landscape of oncology, the intersection of precision medicine, testing reimbursement, and patient care has become increasingly crucial. Recently, Flatiron Health and Exact Sciences embarked on a groundbreaking partnership aimed at advancing clinical evidence generation for molecular residual disease (MRD) testing in cancer patients. This collaboration not only underscores the growing significance of […]

In the realm of clinical development, where the dance between innovation and regulation takes center stage, a recent announcement by the FDA has ignited sparks of anticipation within the oncology community. The FDA’s acceptance for priority review of a supplemental Biologics License Application for Keytruda in resectable, locally advanced head and neck squamous cell carcinoma […]

In the realm of knee osteoarthritis and obesity treatment, the cost-effectiveness of tirzepatide, a glucagon-like peptide 1 receptor agonist (GLP-1 RA), holds significant implications for policy decisions and payer negotiations. Recent research has shown that tirzepatide outperforms semaglutide in terms of cost-effectiveness for patients with knee osteoarthritis and obesity, positioning it as a compelling option […]

In the realm of drug pricing policies, a recent webinar delved into the intriguing landscape of Most Favored Nation (MFN) executive orders, the evolving role of pharmacy benefit managers (PBMs), and the broader spectrum of drug pricing reforms. The discourse surrounding President Trump’s 2025 drug pricing policies sparked a multifaceted exploration of the implications and […]

In the realm of cutting-edge melanoma treatments, Replimune finds itself embroiled in the intricate web of FDA regulations and approvals for its groundbreaking therapy, RP1. As the quest for efficacious therapies in advanced melanoma intensifies, the path to FDA approval for RP1 remains shrouded in uncertainty. In the intricate dance between Replimune and the FDA, […]

Hey there, Cancer Crusaders! Get ready to dive into the latest breakthrough in oncology treatment as the FDA has given the green light to subcutaneous pembrolizumab for solid tumor indications. This approval is a game-changer, promising enhanced treatment efficacy while keeping a keen eye on safety and effectiveness. Swift Administration, Powerful Results In a move […]

In the intricate world of combatting Clostridioides difficile infection, a recent study funded by the revered National Institutes of Health has unveiled a potential key to unlock therapeutic interventions against this formidable foe. Delving deep into the molecular realm, the study highlights the Glucosyltransferase domain (GTD) as a promising target for disrupting the vicious cycle […]

Short-chain fatty acids (SCFAs) are emerging as potential game-changers in the treatment of Clostridioides difficile infection (CDI), a pressing concern in both America and Europe. While traditional antibiotics remain the primary approach, their disruptive impact on the gut microbiota often leads to recurrent infections. In contrast, fecal microbiota transplantation (FMT) has shown promise in restoring […]

As we commemorate Prostate Cancer Awareness Month in September, we delve into the realm of cutting-edge advancements revolutionizing the landscape of prostate cancer therapy. Dr. Daniel Petrylak, a distinguished figure in oncology and urology at Yale School of Medicine, sheds light on the most exhilarating progressions in prostate cancer treatment. Embarking on a new era […]

Breast cancer stands as a prevalent concern among women in the United States, with over 300,000 new cases of invasive breast cancer projected to be diagnosed by 2025. Despite being the second-leading cause of cancer death in women, the 5-year relative survival rate can reach nearly 99% when detected at its earliest stage. The treatment […]

In the midst of recent controversies surrounding the dismissal of 18 inspectors general, an essential report highlighting the need for reforms in the FDA’s accelerated approval process has surfaced, shedding light on crucial areas for improvement and oversight. Released by the HHS’ Office of the Inspector General (OIG) during the final days of the Biden […]

In the realm of cutting-edge biotech advancements, a riveting discussion ensues over the early clinical trial data emanating from the fusion of the B-cell maturation antigen–targeting bispecific antibody linvoseltamab with the potent proteasome inhibitors carfilzomib and bortezomib in the context of relapsed/refractory multiple myeloma. The discourse sheds light on the alluring response rates, the adept […]

The mere mention of the word “tumor” can send shivers down anyone’s spine, conjuring feelings of fear and uncertainty. The questions that follow are often overwhelming: How severe is it? Is it cancerous? What are the treatment options? How will it impact my loved ones and finances? In the relentless battle against cancer, immunotherapy emerges […]

Cancer, a cunning adversary, employs various tactics to elude the immune system, making it a formidable foe in the realm of medicine. Its rapid cell division and resistance to conventional treatments render it highly aggressive, especially in the case of solid tumors with their intricate blend of cell types and characteristics. These tumors not only […]

In the realm of chronic lymphocytic leukemia (CLL) treatment, the role of ibrutinib has been a subject of significant interest and scrutiny. A recent comprehensive study delved into the real-world data of over 3300 patients with relapsed/refractory CLL who underwent treatment with ibrutinib. This study, considered the longest of its kind, not only reaffirmed the […]

In the realm of melanoma treatment, the presence of NRAS mutations has emerged as a significant indicator of favorable responses to immunotherapy, as emphasized by Dr. Richard W. Joseph, MD. Recent clinical trial findings have shed light on the enhanced efficacy of immunotherapeutic interventions in patients harboring NRAS mutations compared to those with wild-type NRAS. […]

Dr. Martin Dietrich delves into the intricate world of patients developing resistance to KRAS inhibition and the challenges faced by healthcare providers in managing this resistance. The resistance mechanisms to KRAS G12C are multifaceted, posing a significant challenge as effective subsequent treatment strategies are currently limited to experimental clinical trials. These mechanisms encompass a spectrum […]

In the realm of Type 2 Diabetes (T2D) treatment, a groundbreaking Japanese study has unearthed a fascinating correlation between eating behaviors and the success of glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy. This research sheds light on how external eating patterns could be pivotal in determining weight loss and glycemic improvements for individuals with T2D […]

In the realm of EGFR-mutated advanced non–small cell lung cancer (NSCLC), the landscape of treatment has been evolving rapidly, ushering in a new era of next-generation targeted therapies. Notably, the phase 3 MARIPOSA trial (NCT04487080) has been pivotal in introducing a combination EGFR-targeting regimen that challenges the standard-of-care osimertinib. In a recent Case-Based Roundtable event, […]

Targeted therapies for chronic lymphocytic leukemia (CLL) are pivotal in improving patient outcomes, yet their effects on blood cell behavior remain a lesser-explored domain with significant clinical implications. Recent research has shed light on how specific therapies influence red blood cell (RBC) aggregation, a factor intricately linked to cardiovascular complications. This study not only delves […]

Tatum Bioscience, a medtech startup based in Sherbrooke, Quebec, is making waves with its groundbreaking immunotherapy approach that offers a more scalable solution for cancer treatment compared to traditional vaccines. The company recently showcased promising results in a study that demonstrated the efficacy of its cancer vaccine in preclinical trials. The Breakthrough Study Published in […]

In the mesmerizing realm of cancer biology, a recent report has cast a spotlight on the enigmatic players known as Cancer-Associated Fibroblasts (CAFs) and their pivotal role in the intricate dance of melanoma metastases. This groundbreaking study, published in the esteemed journal Pigment Cell & Melanoma Research, unveils a realm of potential novel therapeutic targets […]

In a groundbreaking development, Merilog (insulin-aspart-szjj) has emerged as the premier rapid-acting insulin biosimilar to Novolog (insulin aspart), revolutionizing glycemic control for adults and adolescents grappling with type 2 diabetes. This milestone, marked by the FDA’s approval of Merilog, not only signifies a new era in diabetes management but also heralds a beacon of hope […]

Navigating Biosimilars: Expert Perspectives on Integration, Challenges, and Future Trends Within Health Systems In a dynamic Q&A session, we delve into the insights of three influential figures in healthcare management and pharmacy: Sophia Humphreys, PharmD, MHA, BCBBS; Robert Gluckman, MD, MACP; and Elie M. Bahou, PharmD, MBA. These experts shed light on the integration, challenges, […]

In the realm of battling Non-Hodgkin Waldenstrom Lymphoma, a glimmer of hope emerges as ImmunityBio unveils groundbreaking findings from their study on CD19 CAR-NK immunotherapy. This innovative approach, free from the shackles of chemotherapy, showcases promising results in treating Waldenström macroglobulinemia, offering a beacon of optimism for patients navigating the treacherous waters of this disease. […]

In the realm of cancer diagnostics, the quest for early detection is a defining battleground. Colorectal cancer (CRC) stands as a formidable foe, ranking as the third most prevalent cancer worldwide and the second leading cause of cancer-related mortality. The urgency to pioneer noninvasive methods for timely CRC detection has spurred a recent study into […]

In the realm of pharmaceutical pricing strategies, Optum Rx has unveiled a groundbreaking approach that promises predictability and transparency, setting a new standard in the industry. This innovative value-based pricing model, known as the Clear Trend Guarantee program, merges guarantees into a unified per-member cost, revolutionizing the landscape of pharmacy benefit management. Led by the […]

Matias Sanchez, MD, a luminary hematologist-oncologist at the esteemed University of Illinois Health, orchestrates a melodic discourse on the symphony of value-based myeloma care amidst the crescendo of game-changing therapeutic developments. His virtuoso performance unveils the harmonious integration of minimal residual disease strategies and avant-garde targeted therapies that resonate within the realm of multiple myeloma […]

Introduction: In a groundbreaking development, Ligufalimab, a cutting-edge antibody therapy, has been granted orphan drug designation by the FDA for the treatment of Acute Myeloid Leukemia (AML). This recognition underscores Ligufalimab’s potential as an innovative immunotherapy that could revolutionize the landscape of AML treatment options. The Power of Orphan Drug Designation: Orphan drug designation is […]

Patient engagement plays a crucial role in enhancing health technology assessments (HTA) for rare diseases by incorporating patient perspectives and real-world experiences into the evaluation process. Rare diseases pose unique challenges to traditional HTA methods due to limited patient populations, scarce data, and diverse clinical manifestations. This necessitates a shift towards patient-centered outcomes research (PCOR) […]

Alberta, Canada, has taken a significant step in its healthcare system by mandating the transition of patients from the originator adalimumab (Humira) to biosimilar versions under its Biosimilars Initiative. This initiative marks a pivotal moment in healthcare policy in the region and aligns with global efforts to promote the use of cost-effective biosimilars. The expansion […]

Introduction: In a groundbreaking development, researchers at the University of California, Los Angeles (UCLA) have unveiled a cutting-edge immunotherapy known as AlloCAR70-NKT. This innovative treatment offers new hope for patients with metastatic kidney cancer, a disease that has historically posed significant challenges in terms of treatment options and outcomes. Unveiling AlloCAR70-NKT: AlloCAR70-NKT is a novel […]

Introduction: In a groundbreaking study, a molecular allergy chip has revolutionized the detection and understanding of allergic asthma. The research, recently published in Allergy, showcased that a staggering 73% of individuals with asthma exhibited sensitization to specific airborne allergens. This innovative chip not only identifies allergic asthma but also paves the way for targeted precision […]

Are you ready to dive into the exciting world of oncology breakthroughs? Buckle up as we dissect the latest findings on the dynamic duo of azacitidine and ruxolitinib in the treatment of advanced myeloproliferative neoplasms (MPNs). Get your scrubs on as we explore how this groundbreaking pairing is turning the tide for patients facing accelerated‐phase […]

Cervical cancer, primarily caused by the human papillomavirus (HPV), poses a significant health risk to women worldwide. Despite advancements in treatment, monitoring disease progression and treatment efficacy remains challenging, especially in cases of metastasis or recurrence. A novel approach utilizing blood tests to detect HPV DNA fragments from tumor cells, known as liquid biopsy, offers […]

In a recent revelation on her podcast, ‘Two T’s in a Pod’, Teddi Mellencamp, the former ‘Real Housewives of Beverly Hills’ star, opened up about the profound impact of a COVID diagnosis on top of her ongoing battle with stage 4 cancer. The dual challenges she faced plunged her into a state of “extreme, extreme […]

In the realm of hematological malignancies, Peripheral T-cell Lymphomas (PTCLs) are notably aggressive, yet devoid of a well-established treatment standard, posing a significant clinical challenge. The emergence of chimeric antigen receptor (CAR) immunotherapy has predominantly focused on combatting B-cell malignancies, leaving a gap in addressing T-cell malignancies. A recent study dives into the innovative realm […]

Dr. Raghuraman Kannan has recently been honored as a Curators’ Distinguished Professor by the University of Missouri Board of Curators, recognizing his exceptional contributions to academia. Alongside nine other esteemed faculty members, he has been bestowed with this prestigious title, signifying the highest level of academic achievement within the university community. A distinguished figure in […]

Ligufalimab, a cutting-edge humanized IgG4 monoclonal antibody targeting CD47, has recently been awarded FDA orphan drug designation for the treatment of acute myeloid leukemia (AML). This prestigious recognition underscores the remarkable potential of ligufalimab in addressing both hematologic malignancies and solid tumors, heralding a new era in therapeutic innovation. The unique design of ligufalimab sets […]

Liver cancer, a once uncommon ailment in the United States, is now on the brink of becoming one of the most prevalent and deadly forms of cancer. The escalating rates of liver cancer cases, particularly hepatocellular carcinoma (HCC) and cholangiocarcinoma, have sparked concerns among medical professionals like Marina Baretti and Mark Yarchoan at the Johns […]

In the realm of immunotherapy research, Creative Biolabs emerges as a beacon of innovation, introducing a groundbreaking array of research toolkits tailored to propel the development of immune-based therapies to new heights. With a surge in the demand for precision tools in this field, the company has swiftly responded by unveiling a suite of advanced […]

Cancer research is advancing at a rapid pace, with new treatments and therapies being developed to combat various types of cancer. One area of focus is on actively recruiting trials for lung cancer, biliary tract cancer, acute myeloid leukemia (AML), and small cell lung cancer. These trials are investigating promising treatments such as ateganosine, spevatamig, […]

The inception of Immune Design in 2008 marked a significant milestone in the realm of immunotherapy, with a focus on developing cutting-edge treatments for cancer, infectious diseases, and allergic conditions. Headquartered in Seattle and with offices in South San Francisco, Immune Design stands as a beacon of innovation in the field of oncology. The company’s […]

In the realm of cancer treatment, the synergy between immunotherapy and traditional methods like chemotherapy and radiotherapy is reshaping the landscape of care for patients with advanced non-small cell lung cancer (NSCLC). A recent systematic review and meta-analysis delves into the efficacy and safety of combining immune checkpoint inhibition with concurrent chemoradiotherapy in individuals with […]

Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment, offering significant survival benefits to patients with various metastatic cancers. However, as the use of ICIs becomes more prevalent, a concerning rise in neurological immune-related adverse events (irAE) has been observed. One such complication is cerebral pseudoprogression, a phenomenon where imaging studies suggest tumor growth when it […]

The Human Immunopeptidome Project (HIPP) stands as a beacon of hope in the realm of immunopeptidomics. The field, driven by technological advancements in mass spectrometry, holds the promise of unraveling the intricate web of peptides associated with human leukocyte antigen (HLA) molecules. As we embark on this odyssey to map the human immunopeptidome, we are […]

Scientists have made a groundbreaking discovery regarding the role of extrachromosomal DNA (ecDNA) in the development and progression of glioblastoma, shedding light on the earliest secrets of brain cancer initiation. Glioblastoma, one of the most aggressive forms of brain cancer in adults, has long posed significant challenges in terms of treatment efficacy and patient survival […]

The landscape of cancer treatment is undergoing a paradigm shift with the emergence of revolutionary personalized cancer vaccines. These groundbreaking therapeutic vaccines are designed not only to treat cancer but also to prevent its recurrence in patients who have undergone conventional treatments. Representing a novel form of immunotherapy, these vaccines work by training the immune […]

In a groundbreaking leap towards advancing cancer treatment, a team of scientists has introduced an innovative AI-powered technique that facilitates the rapid development of personalized immune therapies within a matter of weeks. Departing from the conventional approach of identifying natural immune system matches, this cutting-edge methodology harnesses artificial intelligence to craft precise proteins capable of […]

In the realm of immunotherapy, the pursuit of targeting cancer-specific HLA-peptide complexes has emerged as a beacon of hope. The allure lies in the exquisite potential of mutated neoantigens, which boast both immunogenicity and cancer-specificity. Mass spectrometry (MS)-based immunopeptidomics stands as a pivotal tool in navigating the intricate landscape of identifying naturally presented immunogenic targets […]

In a groundbreaking clinical trial conducted by researchers at the Johns Hopkins Kimmel Cancer Center and its Bloomberg~Kimmel Institute for Cancer Immunotherapy, a novel treatment approach utilizing combination immunotherapy before and after surgery has shown promise for patients with operable mesothelioma. Mesothelioma, a rare and aggressive cancer usually caused by asbestos exposure, has seen few […]

Greetings to all science enthusiasts exploring the intriguing realms of bioinformatics and immunotherapy! As we delve into the captivating world of adaptive and acquired resistance to cancer immunotherapy, let us embark on a journey through the intricate mechanisms that govern this fascinating phenomenon. Immunotherapy, hailed as a groundbreaking approach in the fight against cancer, has […]

Introduction: In the realm of advanced non-small cell lung cancer (NSCLC) treatment, the combination of THIO (ateganosine) and the immune checkpoint inhibitor Libtayo (cemiplimab) has emerged as a beacon of hope for patients who have progressed on multiple prior regimens. The recent findings from the phase 2 THIO-101 clinical trial conducted by MAIA Biotechnology have […]

Introduction The landscape of cancer treatment has been drastically transformed by the advent of immunotherapies, ushering in a new era of hope and possibilities for patients with advanced cancers. The remarkable success of these therapies, characterized by their ability to elicit durable responses, has underscored the immense potential of harnessing the immune system to combat […]

Introduction: Cancer, a multifaceted disease, presents a challenging journey for those affected by it. Real Housewives of Beverly Hills personality, Teddi Mellencamp, has been candidly sharing her battle with Stage 4 cancer, providing insights into her experiences with treatments such as chemotherapy and immunotherapy. In this article, we delve into Teddi’s ongoing struggle with cancer, […]

In a groundbreaking study led by Abby Overacre at the University of Pittsburgh, researchers have discovered a startling link between the consumption of sucralose, an artificial sweetener commonly found in diet products, and the effectiveness of cancer immunotherapy. The findings shed light on how everyday dietary choices can influence the outcomes of cutting-edge cancer treatments, […]

Gavin Herbert, the illustrious founder of Allergan, orchestrates a symphony of scientific brilliance as he hands over the reins of TechImmune LLC to the esteemed infectious disease expert, James Young. This strategic maneuver aims to tackle the formidable challenge of Long Covid, a lingering specter of the COVID-19 pandemic that continues to afflict millions worldwide. […]

Myasthenia gravis (MG), an autoimmune disease impacting the neuromuscular junction, poses significant therapeutic challenges when it becomes refractory, especially in cases linked to rare anti-low-density lipoprotein receptor-related protein 4 (LRP4) antibodies. The introduction of teclistamab, a potent bispecific antibody targeting B cell maturation antigen (BCMA) and CD3, has sparked a new wave of hope in […]

Glioblastoma multiforme (GBM) presents a formidable challenge in the realm of oncology, being a highly aggressive and resistant brain tumor with a distressingly short median survival time post-diagnosis. Emerging from glial cells that provide crucial support to neurons within the brain, GBM’s etiology remains elusive, with factors such as age, radiation exposure, genetic predispositions, and […]

In the realm of biotech manufacturing operations, the process of scaling up poses numerous challenges and considerations. As a manufacturing operations leader, navigating through the complexities of scale-up, scheduling, plant capacity, batch failures, and supply chain management is crucial for ensuring the efficient and effective production of biotechnological products. This article delves into the pragmatic […]

Researchers at the University of California, Los Angeles (UCLA) have made significant strides in the fight against kidney cancer by introducing a groundbreaking immune cell therapy. Unlike existing treatments that are customized for individual patients, this novel approach involves engineered immune cells known as AlloCAR70-NKT, which can be administered to anyone without the need for […]

Small cell lung cancer (SCLC) poses a significant challenge in the realm of oncology due to its aggressive nature and poor survival rates. However, recent research presented at the World Conference on Lung Cancer (WCLC) 2025 has shed light on a promising new avenue for improving immunotherapy outcomes in SCLC patients. The focus of this […]

Perioperative immunotherapy has emerged as a groundbreaking treatment strategy for non-small cell lung cancer (NSCLC), showcasing significant survival benefits for patients undergoing this innovative approach. The utilization of immunotherapy in the perioperative setting has shown promising results, particularly in improving overall survival rates among individuals with NSCLC. The phase 3 KEYNOTE-671 trial has been instrumental […]

Advances in the field of immunotherapy are revolutionizing the treatment landscape for small cell lung cancer, offering new hope for extended survival and potential cures. Dr. Jacob A. Sands, a prominent figure in the oncology field, highlighted the significant impact of immunotherapy on both limited- and extensive-stage small cell lung cancer during an interview with […]

Recognition and testing for ROS1 rearrangements in non-small cell lung cancer (NSCLC) have undergone significant advancements in recent years, transitioning from traditional single-gene techniques like fluorescence in situ hybridization (FISH) to more comprehensive next-generation sequencing (NGS) methods. This shift has enabled the simultaneous detection of multiple actionable alterations, crucial in the context of the expanding […]

Cancer immunotherapy has revolutionized cancer treatment by leveraging the body’s immune system to combat cancer cells effectively. Immune checkpoint inhibitors (ICIs) have been a cornerstone in this field, particularly in activating T cells to attack cancer cells. However, resistance mechanisms in tumors, such as the suppression of tumor-infiltrating lymphocytes (TILs), have limited the efficacy of […]

GLP-1 receptor agonists, commonly prescribed for weight loss and diabetes management, have shown promising potential in improving outcomes for lung cancer patients. Research led by Dr. Sai Yendamuri and Dr. Joseph Barbi from Roswell Park Comprehensive Cancer Center and Columbia University Irving Medical Center revealed that patients using GLP-1 receptor agonists experienced better results compared […]

ImmVira, a pioneering biotechnology company, has unveiled groundbreaking data on its engineered exosome MVR-EX105 at the 2025 International Federation for the Surgery of Obesity and Metabolic Disorders Congress. The company’s lead candidate, EX105, utilizes a bio-derived nano-size delivery system developed on the OVPENS platform to target fat reduction and muscle preservation through the process of […]

Metastatic clear cell renal cell carcinoma (ccRCC) treatment strategies have advanced significantly in recent years, moving beyond single-agent VEGF receptor antagonists to innovative combination therapies. These new regimens, such as doublet combinations of VEGF inhibitors or CTLA-4 inhibitors with PD-1 inhibitors, have shown improved outcomes in terms of response rates and progression-free survival. However, the […]

Phase II trials play a crucial role in assessing the efficacy of therapeutic interventions in patients and determining the optimal treatment regimens to advance to Phase III trials. Typically involving a cohort of 100-300 patients with the target disease, these trials provide valuable insights into both the effectiveness and safety profiles of novel treatments. The […]

In a groundbreaking development, scientists have introduced a novel bacterial therapy for cancer that operates independently of the immune system, potentially transforming treatment for immunocompromised patients. This pioneering approach, developed by a research team led by Professor Eijiro Miyako at the Japan Advanced Institute of Science and Technology (JAIST), in collaboration with Daiichi Sankyo Co., […]

In a recent study published in Nature Immunology, researchers from UT Southwestern Medical Center have shed light on a critical mechanism through which cancer cells harness a hormone-receptor interaction to evade the immune system. The discovery unveils a potential target for novel cancer immunotherapy strategies and holds promise for addressing inflammatory and neurological disorders. Dr. […]

Researchers have found a groundbreaking method to enhance the cancer-fighting capabilities of T cells by targeting a protein called Ant2, which results in a significant boost in their metabolism and efficacy against tumors. This discovery has the potential to revolutionize cancer immunotherapies by strengthening the body’s natural defense mechanisms and offering a more precise and […]

HCW Biologics Inc. experienced a surge in its stock value following the revelation of a groundbreaking advancement in the development of second-generation cancer immunotherapies based on pembrolizumab, a well-known immune checkpoint inhibitor. The company’s proprietary TRBC product discovery platform has successfully engineered fusion molecules that exhibit enhanced immune activation and tumor infiltration, showcasing promising preclinical […]

In a groundbreaking clinical trial, cancer drugs that have been in use for over two decades were reengineered to effectively eliminate aggressive tumors, marking a significant advancement in cancer treatment. The trial conducted at Rockefeller University in New York showcased remarkable results, with two patients diagnosed with melanoma and breast cancer witnessing a complete disappearance […]

Northwell’s Northern Westchester Hospital (NWH) in Mount Kisco has named Dr. Anna Komorowski as the chief of hematology and medical oncology. In her new role, Dr. Komorowski will be responsible for overseeing inpatient and outpatient hematology and cancer services at the hospital, with a focus on improving patient care, service quality, and program expansion. Additionally, […]

Detecting minimal residual disease (MRD) post-frontline treatment for ovarian cancer through surgery and liquid biopsy could play a crucial role in identifying recurrence early and potentially preventing the progression to incurable disease. Research indicates that women with MRD detected via second-look laparoscopy or circulating tumor DNA (ctDNA) testing tend to have significantly worse progression-free survival […]

Two Louisiana cities, New Orleans and Baton Rouge, have recently been recognized as U.S. allergy capitals, highlighting the challenges residents face with pollen allergies. As we transition from summer to fall, it’s crucial to prepare for the upcoming allergy season. Allergies affect millions of Americans annually, causing symptoms like congestion, itchy eyes, runny nose, sneezing, […]

HCW Biologics Inc. has experienced a significant uptick in its stock price following the announcement of its innovative cancer immunotherapy platform. The company’s stock is trading notably higher, with a session volume well above the average. HCW Biologics has revealed the development of second-generation immunotherapeutics based on pembrolizumab, targeting solid tumors such as pancreatic and […]

In the realm of non–small cell lung cancer (NSCLC) treatment, the importance of biomarker testing is on the rise, leading to an increased focus on the efficiency and accuracy of biopsies among lung cancer specialists. The evolving landscape of lung cancer diagnosis has seen bronchoscopic methods become the preferred route for initial tissue acquisition, with […]

Immunotherapy combined with neoadjuvant chemotherapy is proving to be a promising approach in treating early hormone receptor-positive, HER2 negative breast cancer. Recent clinical studies have demonstrated that immune checkpoint inhibitors (ICIs) can significantly increase pathological complete response (pCR) rates in this patient population. Although these findings showcase the potential benefits of integrating immunotherapy into treatment […]

A groundbreaking computational tool named MARQO has emerged as a game-changer in cancer research by enabling rapid single-cell analysis of entire cancer tissue slides. Developed as an open-source platform at the Icahn School of Medicine at Mount Sinai, MARQO revolutionizes the investigation of cellular organization and marker expression in tumors, promising significant advancements in biomarker […]

Resistance to therapy remains a significant challenge in the treatment of lung cancer, leading to decreased treatment effectiveness and poorer outcomes for patients. Despite advancements in treatment modalities such as surgery, chemotherapy, radiation therapy, targeted therapy, and immunotherapy, resistance mechanisms driven by genetic mutations, epigenetic changes, and alterations in the tumor microenvironment persist. Understanding these […]

Jonathan Thompson, MD, MS, a renowned hematology and medical oncology specialist, sheds light on a critical aspect of managing advanced non-small cell lung cancer (NSCLC) – the decision to discontinue immunotherapy after a 2-year period. This strategic approach aims to uphold durable treatment responses while alleviating financial burdens and toxicity concerns. Dr. Thompson underlines the […]

Bispecific antibodies have revolutionized therapeutic antibody engineering by targeting two distinct antigens simultaneously, enhancing efficacy in complex diseases like cancer and autoimmune disorders. These antibodies engage immune cells and disrupt multiple signaling pathways, offering a more comprehensive treatment approach than traditional monoclonal antibodies. However, their complex structure poses pharmacokinetic challenges that can impact efficacy and […]

In the ever-evolving landscape of ovarian cancer treatment, recent breakthroughs in low-grade serous ovarian cancer (LGSOC) and platinum-resistant disease are reshaping the standard of care. Clinical trials presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Society for Medical Oncology (ESMO) Gynaecological Cancers Congress have unveiled promising data on […]

Ionis Pharmaceuticals has achieved a groundbreaking milestone with the FDA approval of Dawnzera, the first RNA-targeted prophylactic for hereditary angioedema (HAE). This innovative drug, previously known as donidalorsen, represents Ionis’ second wholly owned asset and is set to revolutionize the treatment landscape for patients with HAE. Dawnzera offers a superior profile compared to existing prophylactic […]

In the realm of lung cancer care, the strategic utilization of immunotherapy in the perioperative setting plays a crucial role in determining patient outcomes. Jonathan Thompson, MD, MS, an expert in hematology and medical oncology, sheds light on the complexities of making informed decisions regarding adjuvant immunotherapy, particularly for patients with early-stage lung cancer who […]

Nick Salgia, an MD/PhD student, found his passion for studying kidney cancer after encountering a patient with a rare and aggressive subtype during his gap year at an oncology research center. The patient received a novel immunotherapy that sparked Salgia’s interest in understanding and researching kidney cancer further. His journey led him to the lab […]

Clonal neoantigens are emerging as a pivotal mechanism-based biomarker for predicting responses to immunotherapy, particularly in the context of cancer treatment. These persistent DNA mutations, leading to the transformation of normal cells into malignant ones, include clonal mutations that are expressed on the cancer cells’ surface. Immune effector cells released by checkpoint inhibitor therapy can […]

T cells play a crucial role in the immune system by patrolling the body to eliminate infected or cancerous cells. However, cancer cells can evade detection and destruction by T cells, posing a challenge for targeted immunotherapies. Researchers at the Max Delbrück Center for Molecular Medicine (MDC) in Berlin, led by Dr. Armin Rehm and […]

Immunotherapy, a treatment method that involves manipulating the body’s immune response to combat diseases, is a rapidly evolving field with diverse applications ranging from cancer treatment to autoimmune disorders. Recent articles across the Nature Portfolio shed light on groundbreaking research in immunotherapy, unveiling new insights and potential therapeutic strategies. One study explores the role of […]

CD40 agonist antibodies have been a promising avenue in cancer treatment for the past two decades, activating the immune system to target cancer cells. However, their potential has been hindered by severe side effects and limited impact in clinical trials. In a significant breakthrough, researchers at Rockefeller University led by Jeffrey V. Ravetch, MD, PhD, […]

An improved version of an immunotherapy drug has demonstrated significant potential in combatting aggressive cancers during phase-1 trials, researchers report. CD40 agonist antibodies, a category of cancer therapeutics known for activating the immune system against cancer cells in animal models, have historically been associated with severe side effects such as systemic inflammatory responses, low platelet […]

In a significant advancement in cancer treatment, scientists have developed a novel drug that can be directly injected into tumors to combat aggressive forms of breast and skin cancer. This innovative treatment, an enhanced CD40 agonist named 2141-V11, has shown remarkable success in its initial trial involving 12 human participants. Of the participants, six witnessed […]

A groundbreaking cancer immunotherapy drug, known as 2141-V11, has exhibited remarkable efficacy in early clinical trials, showcasing the ability to shrink or eliminate tumors in half of the participants without the severe side effects commonly associated with similar treatments. This innovative drug, an enhanced CD40 agonist antibody, was developed through collaborative efforts by researchers at […]

IO Biotech recently concluded a phase 3 trial for their experimental cancer vaccine, Cylembio, in combination with Merck’s Keytruda for advanced melanoma. While the trial did not meet its primary endpoint, patients receiving the combination therapy showed an improvement in progression-free survival, with a 23% reduction in the risk of disease progression or death. Particularly […]

Corticosteroids are commonly prescribed to alleviate symptoms in lung cancer patients, but recent retrospective study results indicate that their use at the start of immune checkpoint inhibitor therapy may diminish treatment effectiveness. Patients with non-small cell lung cancer (NSCLC) who were on corticosteroids when initiating immunotherapy showed lower response rates, shorter progression-free survival (PFS), and […]

Glioblastoma (GBM) is a deadly brain tumor with complex interactions in the tumor microenvironment. While the role of neutrophils in cancer immunity is recognized, their specific functions within GBM have been less explored. In a recent study, researchers utilized single-cell RNA sequencing (scRNA-seq) alongside machine learning techniques to delve into the heterogeneity of glioblastoma-associated neutrophils […]

The discussion surrounding electroconvulsive therapy (ECT) reveals a potential discrepancy between the information provided to patients and the actual risks and benefits associated with the treatment. A recent survey highlighted that patients often recall being informed about the short-term benefits and temporary memory issues of ECT, while crucial details about long-term risks like permanent memory […]

Scientists from the University of Pittsburgh, in collaboration with the University of Pittsburgh School of Medicine and University of Pittsburgh Cancer Institute, have shed light on how the long noncoding RNA (lncRNA) EPIC1 plays a crucial role in conferring resistance to immunotherapies in tumors. Their research revealed that EPIC1 inhibits the accumulation of cytoplasmic double-stranded […]

A recent groundbreaking study has shed light on the significant impact that autoantibodies, immune proteins typically associated with autoimmune diseases, can have on the response of cancer patients to immunotherapy. Published in Nature, this research presents a potential breakthrough in the realm of oncology, aiming to unravel the mystery behind why some patients benefit from […]

Hydrogels have emerged as promising tools for targeted drug delivery in cancer therapy, offering high biocompatibility, efficient drug encapsulation, and tunable physico-chemical properties. Doxorubicin (DOX), a widely used chemotherapy drug, faces challenges of drug resistance in tumor cells, necessitating innovative delivery systems to maximize its anticancer effects. Natural-based hydrogels like chitosan, alginate, and gelatin, as […]

Digital patient profiles and the extensive use of real-world data are significantly impacting the landscape of oncology clinical trials, as highlighted by Gen Li, PhD, MBA, the president and founder of Phesi. These innovative tools are revolutionizing trial design, enhancing patient recruitment precision, and mitigating the risks associated with trial failures. Phesi’s analysis reveals the […]

At the 2025 Kidney Cancer Research Summit, Dr. Berkay Simsek highlighted the potential role of tumor-associated macrophages (TAMs) in predicting responses to PD-1 inhibitors in metastatic clear cell kidney cancer cases. TAMs, a type of immune cell infiltrating tumors, have varying impacts on cancer treatment efficacy depending on the cancer type. While they are often […]

Recent research findings and initiatives at the Fred Hutch Cancer Center shed light on groundbreaking discoveries in the field of cancer immunotherapy and health indicators. One study highlighted the potential of certain autoantibodies in enhancing cancer patients’ response to immunotherapy, a novel approach that could revolutionize treatment outcomes. Led by Aaron Ring, MD, PhD, this […]

Immunotherapy for cancer has brought about significant advancements in treatment, yet it is not without its challenges. One such side effect that some patients face is immunotherapy-induced type 1 diabetes, which can have serious implications for patient health. Recognizing this issue, a team of researchers from UCLA Health Johnsson Comprehensive Cancer Center delved into the […]

Lactic acid, once considered a byproduct of glycolysis, has now emerged as a crucial player in the interaction between tumors and the immune system. Over time, research has unveiled various roles of lactic acid in pH regulation, signaling through G-protein-coupled receptors, post-translational modifications, and metabolic shuttling within and between cells. In the tumor microenvironment, high […]

Sucralose, a popular artificial sweetener, has raised health concerns due to its potential negative impacts, including systemic inflammation, metabolic diseases, disruptions in gut microbiota, liver damage, and cellular toxicity. Recent research published in Cancer Discovery indicates that individuals consuming high levels of sucralose, commonly found in diet drinks, may exhibit reduced responses to cancer immunotherapy […]

Radiation therapy has transitioned from being a palliative measure to a potent curative option in combating lung cancer, which remains a leading cause of cancer-related mortality globally, surpassing breast, colon, and prostate cancers combined. In India, where over 66,000 succumb to lung cancer annually, the majority are diagnosed at advanced stages, underscoring the critical need […]

Exciting advancements in peanut oral immunotherapy have extended relief to adult patients, showcasing the potential for future research in this field. A study involving 18 patients in the primary efficacy population and 21 in the intention to treat analysis demonstrated promising results. A significant proportion of patients were able to tolerate substantial doses of peanut […]

In a groundbreaking move, Bristol Myers Squibb has committed up to $11.1 billion to collaborate with Germany’s BioNTech in the advancement of their cutting-edge cancer immunotherapy. This strategic partnership aims to revolutionize the field of immunotherapy and potentially transform the landscape of cancer treatment. With the combined expertise of these two industry leaders, the development […]